Aflac's 'Check for Cancer' Campaign Unveiled Amid 379th Trading Volume Rank
On September 8, 2025, , ranking 379th in market activity. The insurer launched its "Check for Cancer" national campaign, partnering with cancer survivor to promote early cancer screenings. , reinforcing the company’s brand alignment with health advocacy. This follows the recent Japan-based Miraito cancer insurance product launch, which has shown strong early adoption across distribution channels including banks and postal services.
Analysts highlight diverging valuation perspectives. , citing growth potential in supplemental health coverage for aging and younger demographics. However, risks persist from weak U.S. sales and declining Japanese premiums. , questioning whether growth is truly undervalued. , reflecting mixed investor sentiment on its strategic initiatives.
To run this back-test accurately I need to pin down a few practical details that aren’t fully specified yet: 1. UniverseUPC-- to rank • “All” U.S. listed stocks (NYSE + NASDAQ + AMEX) – about 6,000 names, heavy data pull • A predefined subset such as the Russell 3000 or the S&P 1500 – lighter and still representative • Something else (please specify) 2. Trade price convention • Buy at the same-day close and sell at next-day close (typical for end-of-day strategies) • Buy at next-day open and sell at next-day close (avoids look-ahead bias) • Another convention? 3. Rebalancing weight • Equal-weight the 500 names each day (default) • Volume-weighted or some other scheme? 4. Transaction costs / slippage • Ignore for now (default) • Apply a fixed cost (e.g., 2 bps per leg) – please specify Once we lock these in, I’ll fetch the necessary daily volume and price data, generate the daily top-500 lists, construct the one-day-hold portfolio returns, and feed them into the back-test engine for 2022-01-03 through today. Let me know your preferred settings and I’ll proceed.

Hunt down the stocks with explosive trading volume.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.



Comments
No comments yet